228401-34-1

Upstream product

• 1121-78-4 5-Hydroxy-2-methylpyridine 
• 99-65-0 meta-dinitrobenzene 
• 585-79-5 m-nitrobromobenzene 
• 402-67-5 3-fluoro-1-nitrobenzene 
• 42732-49-0 5-methyl-3-pyridinol 

Downstream Products

• 228401-35-2 3-[(6-methylpyridin-3-yl)oxy]aniline 
• 1092393-98-0 5-(3-nitrophenoxy)pyridin-2-amine 
• 1092394-56-3 6-(3-nitrophenoxy)imidazo[1,2-a]pyridin-2-amine 
• 1092394-60-9 N-[6-(3-aminophenoxy)imidazo[1,2-a]pyridin-2-yl]cyclopropanecarboxamide 
• 1092394-58-5 N-[6-(3-nitrophenoxy)imidazo[1,2-a]pyridin-2-yl]cyclopropanecarboxamide 
• 1092394-00-7 4-methyl-N-[5-(3-nitrophenoxy)pyridin-2-yl]benzenesulfonamide 
• 1092392-71-6 N-{6-[3-(pyridin-3-ylamino)phenoxy]imidazo[1,2-a]pyridin-2-yl}cyclopropanecarboxamide 
• 1092392-70-5 N-{6-[3-(pyridin-2-ylamino)phenoxy]imidazo[1,2-a]pyridin-2-yl}cyclopropanecarboxamide 
• 1092393-99-1 2-[2-{[(4-methylphenyl)sulfonyl]imino}-5-(3-nitrophenoxy)pyridin-1(2H)-yl]acetamide 
• 1092392-72-7 N-{6-[3-(benzylamino)phenoxy]imidazo[1,2-a]pyridin-2-yl}cyclopropanecarboxamide 
• 1092392-85-2 N-[6-(3-{[isopropylcarbamoyl]amino}phenoxy)imidazo[1,2-a]pyridin-2-yl]cyclopropanecarboxamide 
• 1092392-90-9 C₂₄H₂₀N₄O₃ 
• 1092392-76-1 N-(6-{3-[(phenylsulfonyl)amino]phenoxy}imidazo[1,2-a]pyridin-2-yl)cyclopropanecarboxamide 
• 1092391-40-6 N-[3-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-a]pyridin-6-yl}oxy)phenyl]-3-methylpyridine-2-carboxamide 

Relevant academic research and scientific papers

HETEROBICYCLIC COMPOUNDS AS KINASE INHIBITORS

A compound represented by the formula (I): wherein Z1,Z2,Z3 and Z4 are the following combination, (Z1,Z2,Z3,Z4)=(CR4,N,CR5,C), (N,N,CR5,C), (N,C,CR5,N), (S,C,CR5,C) or (S,C,N,C); R1 and R2 are the same or different and each is (1) a hydrogen atom, (2) a halogen atom, (3) a group bonded via a carbon atom, (4) a group bonded via a nitrogen atom, (5) a group bonded via an oxygen atom or (6) a group bonded via a sulfur atom; R 3 is an amino optionally having substituent(s); R4 and R 5 are the same or different and each is (1) a hydrogen atom, (2) a halogen atom, (3) a group bonded via a carbon atom, (4) a group bonded via a nitrogen atom, (5) a group bonded via an oxygen atom or (6) a group bonded via a sulfur atom; R3 and R4 optionally form a ring optionally having substituent(s); and a group represented by the formula (A) is a cyclic group optionally having substituent(s), or a salt thereof

Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

INHIBITION OF RAF KINASE USING SUBSTITUTED HETEROCYCLIC UREAS

Methods of treating tumors mediated by raf kinase, with substituted urea compounds, and such compounds per se.

MALONAMIDE DERIVATIVES

The present invention relates to malonamide derivatives of formula (I): A-D-B, the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.

Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.